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The RhoA and RhoC GTPases act via the ROCK1 and ROCK2 kinases to promote actomyosin contraction,
resulting in directly induced changes in cytoskeleton structures and altered gene transcription via several
possible indirect routes. Elevated activation of the Rho/ROCK pathway has been reported in several
diseases and pathological conditions, including disorders of the central nervous system, cardiovascular
dysfunctions and cancer. To determine how increased ROCK signalling affected gene expression in
pancreatic ductal adenocarcinoma (PDAC) cells, we transduced mouse PDAC cell lines with retroviral
constructs encoding fusion proteins that enable conditional activation of ROCK1 or ROCK2, and
subsequently performed RNA sequencing (RNA-Seq) using the Illumina NextSeq 500 platform. We describe
how gene expression datasets were generated and validated by comparing data obtained by RNA-Seq with
RT-qPCR results. Activation of ROCK1 or ROCK2 signalling induced signiﬁcant changes in gene expression
that could be used to determine how actomyosin contractility inﬂuences gene transcription in pancreatic
cancer.
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Background & Summary
ROCK1 and ROCK2 are serine/threonine kinases that play key roles in actomyosin cytoskeleton
dynamics1. Acting in response to activation of their upstream regulators RhoA and RhoC GTPases, their
regulation of cytoskeletal architecture gives them central inﬂuence on cell morphology, adhesion and
motility2. ROCK proteins have been discovered to have important roles in differentiation, proliferation
and apoptosis/survival in various cell types3. Given their roles in regulating cell motility, there has been
considerable interest in developing ROCK inhibitors as cancer therapeutics to target invasion and
metastasis4,5. It has more recently become appreciated that Rho-mediated actomyosin dynamics also
impact gene transcription6. Despite many years of research, the effect of ROCK kinases in normal cell
function or in disease states on the regulation of gene expression has not been well characterized.
Pancreatic cancer is the fourth leading cause of cancer-related deaths in the western world7,8. The
most common form is pancreatic ductal adenocarcinoma (PDAC), with the majority of patients carrying
activating KRAS oncogene mutations and mutation or deletion of the TP53 tumour suppressor9.
Furthermore, exome sequencing of pancreatic cancer genomes revealed that ~15% of pancreatic cancer
patients carry ROCK1 gene ampliﬁcations10. Additional genetic alterations that reduce TGFβ signalling,
for example through loss of SMAD4 expression, result in elevated ROCK1-dependent cell contractility
that promotes PDAC progression11,12. As a result, there are clear indications that ROCK signalling
contributes to PDAC growth and progression, likely as an ancillary factor, through mechanisms that
remain to be determined.
To investigate the contribution elevated ROCK signalling has on pancreatic cancer progression, we
used pancreatic cancer cells previously isolated from a mouse PDAC tumour driven by KrasG12D/p53+/−
(ref. 13) and retrovirally transduced constructs encoding ROCK1:ER, ROCK2:ER or GFP:ER fusion
proteins (Fig. 1a)14. The stable fusion protein expressing cell lines allow for conditional activation of
ROCK kinase signalling by the addition of estrogen analogues including 4-hydroxytamoxifen (4HT)
(Fig. 1b), which induces actomyosin contraction through phosphorylation and inhibition of the myosin
phosphatase targeting subunit (MYPT) 1 and direct phosphorylation of the myosin light chains (MLC)
(Fig. 1c). This is aided by LIM kinase 1 and 2 (LIMK1/2) phosphorylation, which in turn phosphorylate
and inactivate the actin-severing coﬁlin proteins leading to actin ﬁlament stabilisation (Fig. 1c). Western
blotting showed expression of GFP:ER, ROCK1:ER or ROCK2:ER fusion proteins in PDAC cells, with
ROCK1:ER or ROCK2:ER expression comparable to endogenous ROCK1 or ROCK2 (Fig. 1d). To
demonstrate conditional ROCK:ER activation, immunoblotting revealed 4HT-induced activation of
ROCK1:ER or ROCK2:ER leading to increased MLC and LIMK1/2 phosphorylation that could be
reversed by the inclusion of the ROCK inhibitor Y27632 (Fig. 1d).
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Figure 1. ROCK kinase activation in PDAC cells. (a) ROCK functional domains and ROCK kinase
expression constructs (CR, cysteine-rich; ER, estrogen receptor hormone binding domain; GFP, green
ﬂuorescent protein; PH, pleckstrin homology domain; RBD, Rho binding domain). (b) Conditional activation
of ROCK kinase by 4-hydroxytamoxifen (4HT). (c) Overview of the ROCK signalling pathway. (d) PDAC cells
expressing GFP:ER, ROCK1:ER or ROCK2:ER fusion proteins were treated with EtOH vehicle or 1 μM 4HT in
the presence or absence of 10 μM Y27632 ROCK inhibitor. Immunoblotting shows ER-fusion proteins,
endogenous ROCK1 and ROCK2, and phosphorylation status of ROCK targets LIMK1/2 (T508/T505) and
regulatory myosin light chain (MLC2; T18S19). Total MLC2 and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) were blotted as loading controls.
www.nature.com/sdata/
SCIENTIFIC DATA | 3:160101 | DOI: 10.1038/sdata.2016.101 2
To study the global effect of ROCK activation on gene expression in mouse PDAC cells, we sequenced
polyA+ mRNAs of GFP:ER expressing cells treated with EtOH vehicle or 4HT, ROCK1:ER expressing
cells treated with 4HT and ROCK2:ER cells treated with 4HT from 3 independent experiments (Fig. 2,
Table 1). The study has been described at the NCBI Bioproject (Data Citation 1), with a description of the
cells used at the NCBI BioSample (Data Citation 2). Primary data are available at the NCBI Sequence
Read Archive (Data Citation 3).
Methods
Cell culture
A pancreatic ductal adenocarcinoma (PDAC) cell line was generated from the pancreatic tumour of a
LSL-KrasG12D/+; LSL-p53ﬂ/+; Pdx1-Cre mouse13. Cells were maintained in High glucose DMEM (Gibco
21969-035) containing 10% fetal bovine serum (FBS; Gibco), 2 mmol l−1 L-glutamine (Gibco), and
penicillin-streptomycin (Gibco).
Generation of stable cell lines
Retroviral infection was used to generate stable PDAC cell lines expressing conditionally active
human ROCK1 (ROCK1:ER), human ROCK2 (ROCK2:ER) or GFP control (GFP:ER). The retroviral
pBABE puro constructs have been described previously14,15. Stable PDAC cell pools were selected using
2.5 μg ml−1 Puromycin using standard procedures.
Western blot analysis
5 × 105 cells were seeded into 6-well plates in DMEM and allowed to settle and grow overnight. Next day,
cells were starved in serum-free DMEM for 9 h, followed by serum-free DMEM with EtOH vehicle or
1 μM 4HT (Sigma H7904) in the presence or absence of 10 μM Y27632 (Tocris 1254). After 16 h of
treatment, whole cell lysates were prepared in cell lysis buffer (1% SDS, 50 mM Tris pH 7.5) and protein
concentration determined by Bicinchoninic assay (Sigma). Standard protocols were used for Western
blotting. Signals were detected by infrared imaging (Li-Cor Odyssey). Antibodies used: ROCK1
(BD-611136), ROCK2 (BD-610623), ROCK1/2 (Millipore 07-1458), phospho-Limk1/2 (Cell Signalling
3841), phospho-MLC2 (Cell Signalling 3674), MLC2 (Cell Signalling 3672), GFP (Abcam ab6556),
GAPDH (Millipore MAB374), Alexa-Fluor 680 (life technologies) and DyLight 800 (Thermo Fisher
Scientiﬁc).
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Figure 2. Overview and experimental design of the study.
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RNA isolation
1 ´ 106 cells were seeded into 6-well plates in DMEM and allowed to settle and grow overnight. Next day,
cells were washed three times with serum-free DMEM, then serum-free DMEM with EtOH vehicle or
1 μM 4HT (Sigma H7904) was added to the cells for 24 h. Cells were harvested with Trypsin and total
RNA was extracted using the RNAeasy kit (Qiagen) according to manufacturer’s instructions. RNA was
quantiﬁed using the Nanodrop spectrophotometer (Nanodrop Tech). The Agilent RNA ScreenTape assay
and the Agilent 2200 TapeStation system were used to determine the RNA integrity number equivalent
(RINe).
RNA sequencing
Total RNA was used to generate an oligo dT-enriched library with the Illumina TruSeq RNA Library
Preparation kit v2.0. RNA fragmentation yielded fragments for use in preparation of the DNA library
ranging from 120 to 210 nucleotides with a median of 155 nucleotides. Quality and quantity of the DNA
library was assessed using the Agilent 2100 Bioanalyzer and the Qubit (Thermo Fisher Scientiﬁc),
respectively. The library was run on the Illumina NextSeq 500 platform using the High Output 75 cycles
kit (2 × 36 cycles, paired-end reads, single index).
RNA sequence analysis
Quality control checks of raw RNA-Seq data ﬁles were done with fastqc (http://www.bioinformatics.
babraham.ac.uk/projects/fastqc/) and fastq_screen (http://www.bioinformatics.babraham.ac.uk/projects/
fastq_screen/). RNA-Seq reads were aligned to the mouse genome (GRCm38.75) using TopHat2.0.10
(ref. 16) and BAM ﬁles were further processed with HTseq0.5.4p3 (http://www.huber.embl.de/users/anders/
HTSeq/doc/count.html) using standard conﬁgurations. The percentage of aligned reads was 88.6%± 2.0%
(mean± s.d.). Differential analysis of count data was performed by the DESeq2 package (DESeq2)17.
Regularized log transformation was used to transform the DESeq2 data for principal component analysis.
Quantitative PCR
Total RNA was used to synthesize complementary DNA with the QuantiTect Reverse Transcription Kit
(Qiagen). Quantitative polymerase chain reactions (qPCR) were set up with the DyNAmo HS SYBR
Green qPCR Kit (Thermo Fisher Scientiﬁc) and primers for Ptgs2, Tff3, Tnc, Cd44, Cyr61 or Gapdh
(Quantitect Primer Assay, Qiagen). Reactions were run and analysed using the 7500 Fast Real-Time PCR
System (Applied Biosystems).
Data Records
Unprocessed RNA sequencing reads have been deposited as fastq ﬁles at the National Center for
Biotechnology Information (NCBI) Sequence Reads Archive (SRA) with the reference SRP081135.
In addition, a project overview has been submitted as the BioProject reference PRJNA327913 (http://
www.ncbi.nlm.nih.gov/bioproject/) (Data Citation 1) with a description of the BioSample reference
SAMN05361890 (http://www.ncbi.nlm.nih.gov/biosample/) (Data Citation 2).
The fastq ﬁles correspond to three independent experimental replicates (Experiment numbers 1–3) for
the PDAC expressing GFP:ER cells treated with EtOH vehicle control or 4HT, or for the ROCK1:ER or
ROCK2:ER expressing cells treated with 4HT as indicated in Table 1. Forward (R1) and reverse (R2)
reads have been combined, with SRA accession numbers for the combined sequencing results also
indicated in Table 1 (Data Citation 3). Please also see the associated Metadata Record.
Experiment Fusion protein Treatment Data File ID Total sequence reads SRA accession
1 GFP:ER Ethanol (vehicle) 1-EX1-GFP-EtOH 3.8E+07 SRR4015461
1 GFP:ER 4HT (1 μM) 2-EX1-GFP-4HT 6.4E+07 SRR4015530
1 ROCK1:ER 4HT (1 μM) 3-EX1-ROCK1–4HT 5.8E+07 SRR4015566
1 ROCK2:ER 4HT (1 μM) 4-EX1-ROCK2-4HT 6.2E+07 SRR4015572
2 GFP:ER Ethanol (vehicle) 5-EX2-GFP-EtOH 6.8E+07 SRR4014833
2 GFP:ER 4HT (1 μM) 6-EX2-GFP-4HT 6.3E+07 SRR4015468
2 ROCK1:ER 4HT (1 μM) 7-EX2-ROCK1-4HT 5.7E+07 SRR4015485
2 ROCK2:ER 4HT (1 μM) 8-EX2-ROCK2-4HT 7E+07 SRR4015492
3 GFP:ER Ethanol (vehicle) 9-EX3-GFP-EtOH 6.1E+07 SRR4015510
3 GFP:ER 4HT (1 μM) 10-EX3-GFP-4HT 6.3E+07 SRR4015519
3 ROCK1:ER 4HT (1 μM) 11-EX3-ROCK1-4HT 6.1E+07 SRR4015548
3 ROCK2:ER 4HT (1 μM) 12-EX3-ROCK2-4HT 6.3E+07 SRR4015560
Table 1. Description and names of data ﬁles deposited with SRA.
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Technical Validation
Quality control of RNA-Seq data
RNA quality was conﬁrmed using the Agilent RNA ScreenTape assay and the Agilent 2200 TapeStation
system, which revealed RNA integrity number equivalent (RINe) values of 10 for all samples. Following
RNA-seq, principal component analysis indicated that GFP:ER samples that had been treated with EtOH
vehicle or 4HT clustered together while ROCK1:ER and ROCK2:ER samples treated with 4HT clustered
together separate from the GFP:ER grouping (Fig. 3a), consistent with the conditional activation of
ROCK catalytic activity observed by western blotting (Fig. 1d). Quantitative reverse transcription PCR
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Figure 3. Quality control of RNA-Seq data. (a) Principal component plot of RNA-Seq (DESeq2) data
indicating the clustering together of GFP:ER samples treated with vehicle control or 4HT, and ROCK1:ER plus
ROCK2:ER samples treated with 4HT. (b) PDAC cells expressing GFP:ER, ROCK1:ER or (c) ROCK2:ER were
treated with EtOH vehicle or 1 μM 4HT. Ptgs2 and Tff3 mRNA levels relative to Gapdh housekeeping gene
were determined by qPCR. Means± s.e.m., unpaired t-test (n= 3). ***Po0.001. (d) Linear regression plots of
fold change for GFP:ER+4HT versus ROCK1:ER+4HT or (e) GFP:ER+4HT versus ROCK2:ER+4HT obtained
by RNA-Seq (DESeq2 data) compared to RT-qPCR (relative to Gapdh). RNA transcripts up-regulated by
ROCK activation: Ptgs2, Tnc, Cd44 and Cyr61. RNA transcript down-regulated by ROCK activation: Tff3.
R2 of Goodness of Fit with p value (n= 3).
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(RT-qPCR) analyses validated differences in gene expression upon ROCK1:ER or ROCK2:ER activation
identiﬁed by RNA seq, including increased Protaglandin-endoperoxidase 2 (Ptgs2) RNA (Fig. 3b) and
decreased Trefoil factor 3 (Tff3) RNA (Figure 3c). We further validated the changes in gene expression
identiﬁed by RNA seq by comparing fold changes in sequence reads with fold changes determined by
RT-qPCR for Ptgs2, Tff3, Cyr61, Tnc and Cd44 between 4HT treated GFP:ER versus ROCK1:ER (Fig. 3d)
and GFP:ER versus ROCK2:ER (Fig. 3e) conditions. In both cases, the fold-changes determined by either
method fell on a single ﬁtted straight line with R2> 0.95 and Po0.05 (Fig. 3d,e). Although there was
good agreement between RNA seq and RT-qPCR for this limited gene set, it is possible that the analytical
methods used may have underestimated gene expression levels18.
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